Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.17 USD | -3.51% | -1.55% | -28.33% |
Financials (USD)
Sales 2024 * | 529M | Sales 2025 * | 681M | Capitalization | 3.11B |
---|---|---|---|---|---|
Net income 2024 * | -1M | Net income 2025 * | 120M | EV / Sales 2024 * | 6.15 x |
Net Debt 2024 * | 139M | Net Debt 2025 * | 24.31M | EV / Sales 2025 * | 4.61 x |
P/E ratio 2024 * |
-1,736
x | P/E ratio 2025 * |
27.2
x | Employees | 517 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.75% |
Latest transcript on Amicus Therapeutics, Inc.
1 day | -1.50% | ||
1 week | -0.09% | ||
Current month | -10.53% | ||
1 month | -8.59% | ||
3 months | -16.15% | ||
6 months | -4.44% | ||
Current year | -25.72% |
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Simon Harford
DFI | Director of Finance/CFO | 64 | 23-08-20 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Lynn Bleil
BRD | Director/Board Member | 60 | 18-09-10 |
Burke W. Whitman
BRD | Director/Board Member | 68 | 19-06-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.91% | 16 M€ | -7.62% | ||
0.32% | 0 M€ | 0.00% | - | |
0.29% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 10.17 | -3.51% | 4 002 520 |
24-04-24 | 10.54 | -1.59% | 1,821,018 |
24-04-23 | 10.71 | -1.02% | 5,091,023 |
24-04-22 | 10.82 | +1.98% | 4,620,529 |
24-04-19 | 10.61 | +2.71% | 2,888,014 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.72% | 3.11B | |
+4.09% | 43.84B | |
+46.28% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- FOLD Stock